Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Abstract Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) during the years 2018–2021. Methods...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2023-06, Vol.78 (6), p.1423-1432
Hauptverfasser:	Suárez-García, Inés, Alejos, Belén, Hernando, Victoria, Viñuela, Laura, Vera García, Mar, Rial-Crestelo, David, Pérez Elías, María Jesús, Albendín Iglesias, Helena, Peraire, Joaquim, Tiraboschi, Juan, Díaz, Asunción, Moreno, Santiago, Jarrín, Inma
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - adverse effects Emtricitabine - therapeutic use Heterocyclic Compounds, 3-Ring - adverse effects HIV Infections - drug therapy HIV-1 Humans Lamivudine - adverse effects Original Research Oxazines - therapeutic use Pyridones - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) during the years 2018–2021. Methods We used multivariable regression models to compare viral suppression (VS) [HIV RNA viral load (VL)
ISSN:	0305-7453 1460-2091
DOI:	10.1093/jac/dkad102